Mammostrat®as a tool to stratify breast cancer patients at risk of recurrence during endocrine therapy
John M.S. Bartlett(Edinburgh Cancer Research), U Chetty(Western General Hospital), Brian Z. Ring, Robert S. Seitz, Jeremy Thomas(Western General Hospital), G.R. Kerr(Western General Hospital), Alison F. Munro(Edinburgh Cancer Research), David Cameron(Corewell Health), Hans Christian Pedersen(Edinburgh Cancer Research), Fiona Campbell(University of Birmingham), Ian Kunkler(Edinburgh Cancer Research), Douglas T. Ross(Incyte (United States)), W Jack(Western General Hospital), Laura Johnstone(Edinburgh Cancer Research), Rodney A. Beck
Cited by 119
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k